April 16, 2015
MSD K.K. and Astellas Pharma have agreed to develop a fixed-dose combination of the dipeptidyl peptidase-4 (DPP-4) inhibitor Januvia (sitagliptin) and the selective sodium glucose co-transporter-2 (SGLT-2) inhibitor Suglat (ipragliflozin). The two companies said on April 15 that they have...read more